New combo therapy shows promise for Tough-to-Treat leukemia
NCT ID NCT03118466
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 36 times
Summary
This study tested whether adding the drug lenalidomide to a standard chemotherapy regimen (MEC) could help adults with acute myeloid leukemia (AML) that had come back or not responded to previous treatment. The trial enrolled 41 people aged 18 to 70. The main goal was to see how many patients achieved complete remission (no signs of cancer) or complete remission without full platelet recovery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02062, United States
-
Massachusetts general Hospital
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.